Clinical trial
Anticancer Therapeutic Vaccination Using Telomerase-derives Universal Cancer Peptides in Metastatic Non Small Cell Lung Cancer : A Phase I/II Study
NCT02818426 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Anticancer Therapeutic Vaccination Using Telomerase-derives Universal Cancer Peptides in Metastatic Non Small Cell Lung Cancer : A Phase I/II Study
- Lead sponsor
- Centre Hospitalier Universitaire de Besancon
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 20, 2016
- Completion date
- December 31, 2024
- Enrollment
- 82 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic non-small cell lung cancer